The rise of genome-scale gene expression profiling allowed for identification of biomarkers that help to further subcategorize known groups of breast cancer, among them luminal (ER+/HER2−), HER2-enriched (HER2+) and triple-negative (ER−/PR−/HER2−) types. This evidence concerns the gene ESR1 and breast carcinoma.